Bristol Myers Squibb (BMY) Other financing activities (2009 - 2022)

Bristol Myers Squibb (BMY) has 14 years of Other financing activities data on file, last reported at $179.0 million in Q4 2022.

• Quarterly Other financing activities rose 6066.67% year-over-year to $179.0 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $984.0 million (up 53.51% YoY) and the FY2023 annual result came in at $27.0 million, down 97.26% from the prior year.
• Other financing activities climbed to $179.0 million in Q4 2022 per BMY's latest filing, from $53.0 million in the prior quarter.
• Across five years, Other financing activities topped out at $419.0 million in Q2 2022 and bottomed at -$58.0 million in Q1 2018.
• The 5-year median for Other financing activities is $35.5 million (2020), against an average of $103.0 million.
• The widest annual swing landed in 2019, when Other financing activities slumped 1400.0%; it then surged 17200.0% in 2020.
• Tracing BMY's Other financing activities over 5 years: stood at $1.0 million in 2018, then tumbled by 1400.0% to -$13.0 million in 2019, then soared by 2230.77% to $277.0 million in 2020, then plunged by 101.08% to -$3.0 million in 2021, then jumped by 6066.67% to $179.0 million in 2022.
• Per Business Quant, the three latest BMY Other financing activities figures stand at $179.0 million (Q4 2022), $53.0 million (Q3 2022), and $419.0 million (Q2 2022).

Peer Comparison